This article explains how a single large dose of azithromycin taken once a week came to protect people with advanced HIV from disseminated Mycobacterium avium complex (MAC), a serious bloodstream and organ infection. It covers the clinical trials behind that practice and the CD4 cell count thresholds that have guided when to start and stop it. It also explains why effective antiretroviral therapy (ART) led US guideline panels to recommend that most people starting treatment today do not need this prophylaxis at all. The evidence is strong and the story is a good example of medicine correcting its own course as circumstances change. Each patient with HIV is a person of full worth whose life is worth protecting, and the history shows real progress toward that end.

What disseminated MAC is and who is at risk

MAC is a group of closely related environmental mycobacteria, chiefly Mycobacterium avium and Mycobacterium intracellulare. They live in soil, natural water and household water systems. Nearly everyone is exposed to them, and a healthy immune system keeps them in check. The organism is not spread from person to person in any meaningful way, so avoiding exposure is not practical. The protection that matters is immune function.

In advanced HIV that protection fails. Disseminated MAC typically appears when the CD4 count falls below 50 cells per cubic millimetre. The bacteria then spread into the blood, bone marrow, liver, spleen and lymph nodes. People develop persistent fever, drenching night sweats, weight loss, diarrhoea, anaemia and abdominal pain. Before modern ART, observational studies found that roughly 20 to 40 percent of people with AIDS developed disseminated MAC if they lived long enough with very low CD4 counts. The infection was linked to shorter survival.

The risk is greatest for people whose CD4 count is very low and whose virus is not being controlled. These include people diagnosed late, people who cannot obtain or tolerate ART, and people whose treatment has failed.

How weekly azithromycin earned its place

Azithromycin is a macrolide antibiotic. It was developed in 1980 at the Pliva pharmaceutical company in Zagreb by chemically modifying erythromycin. Erythromycin itself was isolated from a soil bacterium, now called Saccharopolyspora erythraea, found in a soil sample from the Philippines. The organism that threatens these patients lives in soil and water, and one of the most useful defences against it also came from the soil. Many readers will see providence in that.

Azithromycin has two properties that make weekly dosing work. It is concentrated heavily inside white blood cells, including the macrophages where MAC hides. It also leaves body tissues very slowly, with a terminal half-life of roughly 68 hours. As a result, one 1,200 mg dose (two 600 mg tablets) keeps useful drug levels in tissues for days.

The key human trials were randomised and well conducted:

On this evidence, US guidelines named a macrolide (azithromycin or clarithromycin) as the preferred prophylaxis. Weekly azithromycin was attractive because it was taken once a week and had fewer drug interactions than clarithromycin. Azithromycin is approved by the US Food and Drug Administration for preventing disseminated MAC in advanced HIV at 1,200 mg once weekly. A schedule of 600 mg twice weekly appears in guidelines as an alternative but is not the labelled regimen.

The thresholds: starting below 50, stopping above 100

The starting threshold, a CD4 count below 50 cells per cubic millimetre, came straight from the natural-history data showing where the risk rose steeply. Before starting prophylaxis, clinicians are advised to rule out active disseminated MAC, usually with a blood culture. This step matters. Giving one drug to someone who already has an established MAC infection can select for macrolide-resistant bacteria, which would make later treatment much harder. Rifabutin, the alternative drug, also requires that active tuberculosis be excluded, for the same reason.

The stopping threshold came later. Once combination ART became widely available in the late 1990s, many patients' CD4 counts recovered. Investigators then asked whether prophylaxis could safely be stopped. Two placebo-controlled trials answered that question in 2000:

From these trials came the long-standing rule. Prophylaxis could be stopped once the CD4 count had stayed above 100 for at least three months in response to ART. It should be restarted if the count fell back below 50. These were randomised human trials with a clear result, so the evidence for stopping is strong. Stopping reduced side effects, pill burden, cost and pressure toward antibiotic resistance, with no measurable loss of protection.

Why effective antiretroviral therapy changed the recommendation

The more recent change goes further. Current US guidelines for opportunistic infections, developed jointly by the National Institutes of Health, the Centers for Disease Control and Prevention and the HIV Medicine Association of the Infectious Diseases Society of America, no longer recommend primary MAC prophylaxis for adults and adolescents who start ART immediately. This applies even when the CD4 count is below 50. Prophylaxis is still recommended for people with very low counts who are not on fully suppressive ART. For those who are taking it, the guidance is to stop once they are on effective, virus-suppressing therapy, rather than waiting for a particular CD4 number.

Several lines of reasoning support this shift:

In short, the drug did not stop working. Instead, the most effective protection against MAC is a functioning immune system, and effective ART restores it for most patients.

Practical considerations for patients and families

For the person living with advanced HIV, the principles are fairly simple. The guidance is still nuanced enough to warrant a careful conversation with one's own physician:

Informed consent is central here. Patients have every right to understand why a drug is or is not being recommended and to ask what the evidence shows. They can then decide, together with a physician who knows their history, what best serves their health and their family's future. Caring for one's own body in this way is a form of good stewardship.

Key takeaway: Weekly azithromycin is a proven, effective guard against disseminated MAC when the CD4 count falls below 50, but effective antiretroviral therapy restores the body's own defences so well that most people who start it promptly no longer need the antibiotic at all.